Hepatitis B prevention in blood cancer patients with two antiviral drugs
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests whether a newer hepatitis B drug (tenofovir alafenamide) works as well and is as safe as the older drug (tenofovir disoproxil fumarate) for preventing hepatitis B from becoming active in people with blood cancers who are getting treatments that weaken the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 64 years old.
- You have ever had hepatitis B (a positive HBcAb test).
- You are scheduled to receive a stem cell transplant, immunosuppressant treatment, chemotherapy, or anticancer treatment that includes rituximab.
- You are not currently taking antiviral medication for chronic hepatitis B.
- You have no severe kidney problems, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
Hear when a new Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.